Duancheng Guo

Duancheng Guo

Auto-generated profile, based on publicly available information

Duancheng Guo

Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DGDuancheng Guo
Duancheng Guo
YWYuan Wang
Yuan Wang
YCYan Cheng
Yan Cheng
SLShengyou Liao
Shengyou Liao
JHJian Hu
Jian Hu
ZYZengjie Yang
Zengjie Yang
Astrocytes, a major glial cell type in the brain, play a critical role in supporting the progression of medulloblastoma (MB), the most common malignant pediatric brain tumor. Through lineage tracing analyses and single-cell RNA sequencing, we demonstrate that astrocytes are predominantly derived from the transdifferentiation of tumor cells in relapsed MB (but not in primary MB), although MB cells are generally believed to be neuronal-lineage committed. Such transdifferentiation of MB cells relies on Sox9, a transcription factor critical for gliogenesis. Our studies further reveal that bone morphogenetic proteins (BMPs) stimulate the transdifferentiation of MB cells by inducing the phosphorylation of Sox9. Pharmacological inhibition of BMP signaling represses MB cell transdifferentiation into astrocytes and suppresses tumor relapse. Our studies establish the distinct cellular sources of astrocytes in primary and relapsed MB and provide an avenue to prevent and treat MB relapse by targeting tumor cell transdifferentiation.

27 November 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SSSaimeng Shi
Saimeng Shi
DGDuancheng Guo
Duancheng Guo
LYLongyun Ye
Longyun Ye
TLTianjiao Li
Tianjiao Li
QFQinglin Fei
Qinglin Fei
WWWeiding Wu
Weiding Wu
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tract tumor with limited clinical treatments. Transforming acidic coiled-coil-containing protein 3 (TACC3) is a component of the centrosome axis and a member of the TACC family, which affect mitosis and regulate chromosome stability and are involved in tumor development and progression. However, the role of TACC3 in PDAC remains elusive. In this study, by exploiting the TCGA database, we found that high TACC3 expression in PDAC is associated with poor prognosis. shRNA-mediated TACC3 knockdown caused S phase arrest of the cell cycle and inhibited proliferation in PDAC cell lines. Through RNA sequencing and protein co-immunoprecipitation combined with mass spectrometry, KIF11 was identified as a protein that interacts with TACC3. TACC3 stabilizes and regulates KIF11 protein expression levels in PDAC cells through physical interaction. Knockdown of TACC3 or KIF11 resulted in abnormal spindle formation during cell division both in vitro and in vivo. Pharmacological inhibition of TACC3 or KIF11 can suppress tumor cell proliferation and promote apoptosis. Our studies further demonstrated that high expression of TACC3 and KIF11 mediated the resistance of PDAC to gemcitabine, and deficiency of TACC3 or KIF11 increased the sensitivity of PDAC cells to chemotherapy. In conclusion, our study reveals the fundamental role of TACC3 expression in PDAC cell proliferation and chemoresistance, suggesting that TACC3 can be used as a molecular marker to evaluate the prognosis of PDAC.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
JWJinyan Wang
Jinyan Wang
SPShuangyue Pan
Shuangyue Pan
LBLu Bai
Lu Bai
BLBin Li
Bin Li
TLTiantian Liu
Tiantian Liu
XHXichun Hu
Xichun Hu
Triple‐negative breast cancer (TNBC) is an aggressive subtype characterized by poor prognosis because of a lack of effective therapeutic agents. Changes in extracellular matrix (ECM) composition, particularly type I collagen density, significantly influence crucial cellular activities. However, the association between type I collagen density and TNBC progression remains unclear. This study finds that type I collagen density and mechanical characteristics of lesions predict the pathological grade and malignant progression of TNBC patients. The results of transcriptomics and metabolomics studies suggest that high‐density type I collagen promotes TNBC ferroptosis. Further in vitro experiments indicate that high‐density type I collagen promotes ferroptosis in TNBC cells through spermidine/spermine N1‐acetyltransferase 1 (SAT1)/argininosuccinate synthase (ASS1)‐induced glutamine (Gln) accumulation. Moreover, in vitro co‐culture and in vivo experiments reveal that high‐density type I collagen increases the uptake of Gln in TNBC cells, leading to Gln deprivation of IFN‐γ + CD8 + T cells in the tumor microenvironment, resulting in higher level of immunosuppression. Combination of ferrostatin 1 and anti‐PD‐1 therapy reverses high‐density collagen‐induced tumor progression of TNBC. The clinical samples further verify the role of collagen density in TNBC. This study reveals that high‐density type I collagen participates in TNBC progression partly through immunosuppression induced by Gln accumulation‐related ferroptosis.

1 June 2021 in STAR Protocols
Verified
Journal Article
Open access
YYYijun Yang
Yijun Yang
YQYanghui Qu
Yanghui Qu
YCYan Cheng
Yan Cheng
DGDuancheng Guo
Duancheng Guo
QFQianhai Fan
Qianhai Fan
ZYZengjie Yang
Zengjie Yang
This protocol provides the procedures for isolating differentiated tumor cells from medulloblastoma (MB) in mice. Procedures for transplantation into cerebella are also included to examine the tumorigenesis of differentiated MB cells. This protocol outlines the detailed steps required for (1) isolation of tumor cells from mouse MB, (2) purification of differentiated tumor cells by fluorescence-activated cell sorting, and (3) transplantation of tumor cells into cerebella. This protocol is useful to purify differentiated tumor cells for investigating mechanisms underlying MB progression.